Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $69.8 million, up 24% year over year
- ➤Q3 net loss $22.6 million; diluted loss per share $0.37
- ➤2026 revenue guidance raised to greater than $240 million
- ➤BYSANTI commercial launch expected in Q4 2026
- ➤Quimilza BLA under FDA review; December 12, 2026 PDUFA target
Expert Statements
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude,”
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive Phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in Delayed Sleep-Wake Phase Disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value.”
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results PR Newswire
* Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 * Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 * Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting * NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 * BYSANTI™ commercial launch expected in Q4 2026 * Quimilza™ BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.